P. R. L. de Almeida

Chronic hepatitis C genotype 1 virus: who should wait for treatment?

C. Tovo, A. A. de Mattos, P. R. L. de Almeida, 2014, World journal of gastroenterology.

Acute hepatitis C in Brazil: Results of a national survey

Adalgisa S P Ferreira, L. Lewis-Ximenez, M. G. Ferraz, 2011, Journal of medical virology.

Antiretroviral therapy does not affect response to chronic hepatitis C therapy in HIV-coinfected patients.

C. Tovo, D. Kliemann, A. A. de Mattos, 2016, Journal of infection in developing countries.

[Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital].

B. Santos, C. Tovo, A. A. de Mattos, 2006, Arquivos de gastroenterologia.

IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS

C. Tovo, A. A. de Mattos, A. A. Feltrin, 2016, Revista do Instituto de Medicina Tropical de Sao Paulo.

Pegylated interferon and ribavirin in real life: Efficacy versus effectiveness

C. Tovo, Â. Z. de Mattos, P. R. L. de Almeida, 2010, Hepatology.

[Interferon-alpha and ribavirin therapy on chronic hepatitis C virus infection: the experience of Rio Grande do Sul State Health Department, Brazil].

A. Alves, A. Brandão, P. R. L. de Almeida, 2003, Arquivos de gastroenterologia.

Suggestion of a dual‐functional agent for future trials in nonalcoholic fatty liver disease

C. Tovo, A. A. de Mattos, Â. Z. de Mattos, 2010, Hepatology.

Treatment of hepatitis C with peginterferon and ribavirin in a public health program.

P. Picon, C. Tovo, A. A. de Mattos, 2009, Hepato-gastroenterology.